A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®
- 25 November 2009
- Vol. 28 (5) , 1209-1216
- https://doi.org/10.1016/j.vaccine.2009.11.030
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Evaluation of smallpox vaccines using variola neutralizationJournal of General Virology, 2009
- Vaccinia Virus Extracellular Enveloped Virion Neutralization In Vitro and Protection In Vivo Depend on ComplementJournal of Virology, 2009
- Electrocardiography Screening for Cardiotoxicity after Modified Vaccinia Ankara VaccinationThe American Journal of Medicine, 2009
- Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virusProceedings of the National Academy of Sciences, 2008
- Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protectionJournal of Clinical Investigation, 2008
- Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challengeVaccine, 2007
- Induction of Natural Killer Cell Responses by Ectromelia Virus Controls InfectionJournal of Virology, 2007
- Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccineVaccine, 2005
- Development of a Novel Vaccinia‐Neutralization Assay Based on Reporter‐Gene ExpressionThe Journal of Infectious Diseases, 2003
- Clinical Responses to Undiluted and Diluted Smallpox VaccineNew England Journal of Medicine, 2002